Boundless Bio (BOLD) Common Equity (2023 - 2026)
Boundless Bio (BOLD) posted quarterly Common Equity of $86.4 million for Q1 2026, down 36.76% year-over-year from $136.6 million in Q1 2025, and down 12.44% quarter-over-quarter from $98.7 million in Q4 2025.
Boundless Bio (BOLD) Common Equity (2023 - 2026) Analysis & Trends
Boundless Bio (BOLD) has reported Common Equity for 4 consecutive years, with $86.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 36.76% year-over-year to $86.4 million; the TTM figure through Mar 2026 stood at $86.4 million (down 36.76% YoY), while the FY2025 annual figure was $98.7 million, down 34.51% from the prior year.
- Common Equity slipped to $86.4 million in Q1 2026 per BOLD's latest filing, from $98.7 million in the prior quarter.
- Across five years, Common Equity topped out at $179.2 million in Q2 2024 and bottomed at -$141.2 million in Q1 2024.
- Historically, Common Equity has averaged $36.1 million across 4 years, with a median of $98.7 million in 2025.
- On a YoY basis, Common Equity climbed as much as 272.57% in 2024 and fell as far as 52.73% in 2024.
- Boundless Bio's Common Equity stood at -$127.1 million in 2023, then surged by 218.54% to $150.6 million in 2024, then slumped by 34.51% to $98.7 million in 2025, then retreated by 12.44% to $86.4 million in 2026.
- Business Quant data shows BOLD's Common Equity at $86.4 million in Q1 2026, $98.7 million in Q4 2025, and $110.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Boundless Bio | 67.35 Mn | 67.35 Mn | - | 65.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 65.98 Mn |
| Mar 31, 2026 | 86.38 Mn |
| Dec 31, 2025 | 98.65 Mn |
| Sep 30, 2025 | 110.17 Mn |
| Jun 30, 2025 | 122.69 Mn |
| Mar 31, 2025 | 136.59 Mn |
| Dec 31, 2024 | 150.64 Mn |
| Sep 30, 2024 | 165.08 Mn |
| Jun 30, 2024 | 179.25 Mn |
| Mar 31, 2024 | -141.18 Mn |
| Dec 31, 2023 | -127.08 Mn |
| Sep 30, 2023 | -116.04 Mn |
| Jun 30, 2023 | -103.87 Mn |
| Mar 31, 2023 | -92.44 Mn |